Clinical Trial Update: QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating QL1706 plus XELOX as neoadjuvant therapy for clinical stage III colon cancer is currently NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• QL1706

Snippet

Sponsor: Qilu Hospital of Shandong University | Conditions: Colon Cancer, MSS/pMMR | Phase 2 | Status: NOT_YET_RECRUITING